$SRPT Sarepta Therapeutics owes its investors, big time.
Possible short term breakout in SRPT above $89 with $96 as a 1-2-1 Fibonacci extension target.
This may be a contrarian trade but maybe sentiment and expectations are so poor it presents a good short squeeze opportunity.
Short interest is high at 21% and increased since the July disappointment.
The average analysts price target is $186 and a BUY rating which is a 100% upside expectation.
Company profile
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.
This may be a contrarian trade but maybe sentiment and expectations are so poor it presents a good short squeeze opportunity.
Short interest is high at 21% and increased since the July disappointment.
The average analysts price target is $186 and a BUY rating which is a 100% upside expectation.
Company profile
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.